A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) (NCT07222332)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Who can join: Review the eligibility criteria below.
Location: Barbara Davis Center for Childhood Diabetes — Aurora, Colorado
Age range: 1 Year to 35 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (138 Sites)
Showing the first 25 of 138 sites.
- Barbara Davis Center for Childhood Diabetes — Aurora, Colorado
- Tallahassee Memorial HealthCare — Tallahassee, Florida
- Children's Hospital of Philadelphia (CHOP) — Philadelphia, Pennsylvania
- Driscoll Children's Hospital — Corpus Christi, Texas
- University of Virginia — Charlottesville, Virginia
- Women's and Children's Hospital — Adelaide,
- Centre for Children's Health Research — Brisbane,
- Austin Health - Repatriation Hospital — Heidelberg West,
- Ipswich Hospital — Ipswich,
- Royal Children's Hospital — Melbourne,
- Southern Adelaide Diabetes & Endocrine Services — Oaklands Park,
- The Royal Melbourne Hospital — Parkville,
- Perth Children's Hospital — Perth,
- Sydney Children's Hospital — Randwick,
- The Children's Hospital at Westmead — Westmead,
- Université Libre de Bruxelles - Hôpital Erasme — Brussels,
- UZ Brussel — Brussels,
- Cliniques universitaires Saint-Luc — Brussels,
- Antwerp University Hospital — Edegem,
- UZ Gent — Ghent,
- UZ Leuven — Leuven,
- Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman — Liège,
- CHU UCL Namur/Site Sainte Elisabeth — Namur,
- Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne — Yvoir,
- Hospital Universitário Maria Aparecida Pedrossian — Campo Grande,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus, Type 1
- Testing an Integrated Care Model Trial — Atlanta, Georgia
- Safety of ENC-201-CED ENCRT — Toronto, Ontario
- Teplizumab in Pediatric Stage 2 Type 1 Diabetes — San Francisco, California
- Allogenic Islet Cell Transplantation — Chicago, Illinois
- Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells — Charleston, South Carolina
- Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes — Stanford, California
Explore by condition: All Diabetes Mellitus, Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.